A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
Study Details
Study Description
Brief Summary
This is a phase III, multi-Center, randomized, placebo-controlled trial to investigate the efficacy and safety of CS1001 in combination with Oxaliplatin and Capecitabine (CAPOX) chemotherapy in first-line subjects with unresectable locally advanced or metastatic gastric adenocarcinoma (GC) or gastro-esophageal junction (GEJ) adenocarcinoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: CS1001 monoclonal antibody in combination with Oxaliplatin and Capecitabine |
Drug: CS1001 monoclonal antibody
Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
Drug: Oxaliplatin
Administered as an IV infusion on Day 1 Q3W
Drug: Capecitabine
Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
|
| Placebo Comparator: CS1001 placebo in combination with Oxaliplatin and Capecitabine |
Drug: CS1001 placebo
Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
Drug: Oxaliplatin
Administered as an IV infusion on Day 1 Q3W
Drug: Capecitabine
Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
|
Outcome Measures
Primary Outcome Measures
- Progression-free survival (PFS) evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to approximately 27 months]
- Overall survival (OS) [from the date of randomization to the first date of recorded all-cause death, assessed up to approximately 38 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years but ≤ 75 years
-
Being able to follow the protocol requirements as per investigator's evaluation.
-
Provide written informed consent before any protocol-related procedure (that is not a part of subject's routine care) is carried out.
-
Unresectable locally advanced or metastatic gastric carcinoma (GC) or gastro-esophageal junction (GEJ) carcinoma, and have histologically confirmed simple adenocarcinoma.
-
The subject may have at least a measurable lesion or an evaluable lesion, if not measurable; the investigator will carry out evaluation according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 within 28 days prior to randomization.
-
Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
-
Expected survival ≥ 3 months.
-
Subject must not have received systemic treatment (including HER2 inhibitor) for advanced or metastatic gastric carcinoma.
-
Subject must provide tumor tissue samples for biomarker analysis in order to determine the expression of PD-L1.
-
Permitted prior treatment: Subjects with GC or GEJ carcinoma priorly treated with adjuvant or neoadjuvant therapy, who experience clinical progression of disease at least 6 months after last dose are allowed to be enrolled.
-
Subjects must have adequate organ function as assessed in the laboratory tests
-
Subjects with active hepatitis B or active hepatitis C must receive antiviral treatment for at least 14 days prior to the first dose of study treatment and pass the hepatitis B virus (HBV) DNA titer test (≤ 500 IU/mL or 2500 copies/mL) and hepatitis C virus (HCV) RNA test (≤ lower limit of detection) before being enrolled. The subject should be willing to continue effective anti-viral treatment during the study.
-
Female subject with childbearing potential must have negative serum pregnancy test result at screening, except for those with available sterilization operation record or post-menopausal subjects. Female subject with childbearing potential or male subjects and their partners must agree to take effective contraceptive measures from the day of signing ICF till at least 6 months after the last dosing of investigational product.
Exclusion Criteria:
-
Known HER-2 positivity.
-
A known additional primary malignancy that occurred within 5 years prior to the first dose of investigational treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
-
Known primary central nerve system (CNS) tumor or meningeal metastasis, or unstable CNS metastasis (symptomatic within 4 weeks before first dose of investigational product, requiring corticosteroid treatment, or without radiologic evidence supporting stable status for over 4 weeks prior to the first dose of investigational product).
-
Any severe or uncontrolled systemic disease, for example diabetes mellitus or hypertension, that may increase the risk associated with participation or investigational product administration, or compromise subject's ability to receive investigational product, as per investigator's judgment.
-
Known positive human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
-
Has had prior chemotherapy, immune therapy, biological therapy (including cancer vaccine, cytokine therapy or growth factors to control cancer) used as systemic treatment for cancer, within 14 days before the first dose of investigational product.
-
Any prior treatment of antibody/drug that targets at T-cell coregulatory proteins or immune checkpoints pathways(including anti-PD-1, anti-PD-L1, anti-CTLA4, anti-TIM3, anti-LAG3 antibody, etc.).
-
Subjects with conditions that in the investigator's opinion are not suitable for participating in this trial.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing Cancer Hospital | Beijing | China |
Sponsors and Collaborators
- CStone Pharmaceuticals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CS1001-303